Deutsche Bank Starts United Therapeutics Corp. (UTHR) at Buy; Attractive Risk/Reward into FREEDOM M

Deutsche Bank initiates coverage on United Therapeutics Corp. (NASDAQ: UTHR) with a Buy.

Deutsche analyst says, "UTHR develops drugs for pulmonary arterial hypertension. It already sells IV, SQ & inhaled Remodulin for PAH & is developing an oral version - w/ ph 3 data expected in Jun & Sep '11. We initiate coverage on UTHR with a Buy, based on our analysis that phase 3 trials succeed & oral Remodulin will achieve $750M+ in peak sales."

For more ratings news on United Therapeutics Corp. click here and for the rating history of United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $66.05 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• United Therapeutics completes enrollment in PPF lung fibrosis trial
• Deutsche Bank Downgrades Workday (WDAY) to Hold
• ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy